These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 21280530

  • 1. Apolipoprotein B level in patients with type 2 diabetes who achieved goal of low density lipoprotein cholesterol and non-high density lipoprotein cholesterol.
    Sathavarodom N, Boonyavarakul A.
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S166-72. PubMed ID: 21280530
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [Abstract] [Full Text] [Related]

  • 3. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2011 Jul 01; 108(1):40-6. PubMed ID: 21565322
    [Abstract] [Full Text] [Related]

  • 4. The association of apolipoprotein B and low density lipoprotein with cardiovascular risk factors in the Thai population.
    Krittayaphong R, Chotinaiwatarakul C, Kangkagate C, Bhuripanyo K, Mahanonda N.
    J Med Assoc Thai; 2006 Nov 01; 89 Suppl 5():S1-7. PubMed ID: 17722296
    [Abstract] [Full Text] [Related]

  • 5. Effect of atorvastatin on type 2 diabetic dyslipidemia.
    Save V, Patil N, Moulik N, Rajadhyaksha G.
    J Cardiovasc Pharmacol Ther; 2006 Dec 01; 11(4):262-70. PubMed ID: 17220473
    [Abstract] [Full Text] [Related]

  • 6. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.
    Am Heart J; 2006 May 01; 151(5):975.e1-9. PubMed ID: 16644314
    [Abstract] [Full Text] [Related]

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 8. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 01; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Strategies for optimizing lipid management.
    Ballantyne CM.
    Postgrad Med; 2004 Sep 01; 116(3 Suppl):13-20. PubMed ID: 19667671
    [Abstract] [Full Text] [Related]

  • 11. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
    Temelkova-Kurktschiev T, Hanefeld M.
    Exp Clin Endocrinol Diabetes; 2004 Feb 01; 112(2):75-9. PubMed ID: 15031770
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
    Ferrer-García JC, Sanchez-Ballester E, Albalat-Galera R, Berzosa-Sanchez M, Herrera-Ballester A.
    J Cardiovasc Pharmacol Ther; 2008 Sep 01; 13(3):183-8. PubMed ID: 18635754
    [Abstract] [Full Text] [Related]

  • 17. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.
    Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J.
    J Intern Med; 2010 Dec 01; 268(6):567-77. PubMed ID: 21091808
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.